About talazopari b
PARP inhibitor anticancer medicine
Used for
- Treats certain advanced prostate cancers with inherited or tumor DNA-repair changes.
- Treats some HER2-negative breast cancers with inherited BRCA mutations.
Usual adult dose
Usually 1 mg by mouth once daily; dose may be adjusted for kidney function or side effects.
Common side effects
- Low blood cell counts, including anemia, low platelets, or low white cells
- Tiredness or weakness
- Nausea, reduced appetite, or diarrhea
- Hair loss or headache
Important warnings
- Can cause serious bone marrow suppression and infections or bleeding.
- Rarely causes myelodysplastic syndrome or acute myeloid leukemia.
- May harm an unborn baby; effective contraception is required during treatment.
- Kidney problems can increase exposure and require dose adjustment.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for at least 7 months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for at least 1 month after the last dose.
Interactions
- Strong P-glycoprotein inhibitors can increase talazoparib levels.
- P-glycoprotein inducers can reduce talazoparib levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.